Your browser doesn't support javascript.
loading
Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR.
Mendelsohn, Simon C; Mbandi, Stanley Kimbung; Fiore-Gartland, Andrew; Penn-Nicholson, Adam; Musvosvi, Munyaradzi; Mulenga, Humphrey; Fisher, Michelle; Hadley, Katie; Erasmus, Mzwandile; Nombida, Onke; Tameris, Michèle; Walzl, Gerhard; Naidoo, Kogieleum; Churchyard, Gavin; Hatherill, Mark; Scriba, Thomas J.
Afiliación
  • Mendelsohn SC; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Mbandi SK; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Fiore-Gartland A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Penn-Nicholson A; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Musvosvi M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Mulenga H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Fisher M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Hadley K; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Erasmus M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Nombida O; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Tameris M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925 Cape Town, South Africa.
  • Walzl G; DST/NRF Centre of Excellence for Biomedical TB Research; South African Medical Research Council Centre for TB Research; Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, 7505 Cape Town, South Africa.
  • Naidoo K; Centre for the AIDS Programme of Research in South Africa (CAPRISA), 4001 Durban, South Africa.
  • Churchyard G; MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, 4001 Durban, South Africa.
  • Hatherill M; The Aurum Institute, 2194 Johannesburg, South Africa.
  • Scriba TJ; School of Public Health, University of Witwatersrand, 2193 Johannesburg, South Africa.
Commun Med (Lond) ; 2(1)2022.
Article en En | MEDLINE | ID: mdl-35342900
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Commun Med (Lond) Año: 2022 Tipo del documento: Article País de afiliación: Sudáfrica
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Commun Med (Lond) Año: 2022 Tipo del documento: Article País de afiliación: Sudáfrica